Added Value of Fecal Calprotectin to Support the Diagnosis of Spondyloarthropathies

REFERENCES

1. 1.↵
   1. Kopylov U,
   2. Starr M,
   3. Watts C,
   4. Dionne S,
   5. Girardin M,
   6. Seidman EG

   . Detection of Crohn disease in patients with spondyloarthropathy: the SpACE capsule study. J Rheumatol 2018;45:498–505.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Cuvelier C,
   2. Barbatis C,
   3. Mielants H,
   4. De Vos M,
   5. Roels H,
   6. Veys E

   .Histopathology of intestinal inflammation related to reactive arthritis. Gut 1987;28:394–401.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Vogl T,
   2. Tenbrock K,
   3. Ludwig S,
   4. Leukert N,
   5. Ehrhardt C,
   6. van Zoelen MA,
   7. et al.

   Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007;13:1042–9.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Menees SB,
   2. Powell C,
   3. Kurlander J,
   4. Goel A,
   5. Chey WD

   . A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol 2015;110:444–54.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Lin JF,
   2. Chen JM,
   3. Zuo JH,
   4. Yu A,
   5. Xiao ZJ,
   6. Deng FH,
   7. et al.

   Meta-analysis: Fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis 2014;20:1407–15.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Cypers H,
   2. Varkas G,
   3. Beeckman S,
   4. Debusschere K,
   5. Vogl T,
   6. Roth J,
   7. et al.

   Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis. Ann Rheum Dis 2015;75:1357–62.

   OpenUrl
7. 7.↵
   1. Rudwaleit M,
   2. van der Heijde D,
   3. Landewé R,
   4. Akkoc N,
   5. Brandt J,
   6. Chou CT,
   7. et al.

   The assessment of spondyloarthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011;70:25–31.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. De Wilde K,
   2. Debusschere K,
   3. Beeckman S,
   4. Jacques P,
   5. Elewaut D

   . Integrating the pathogenesis of spondyloarthritis: Gut and joint united? Curr Opin Rheumatol 2015;27:189–96.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Van Praet L,
   2. Jans L,
   3. Carron P,
   4. Jacques P,
   5. Glorieus E,
   6. Colman R,
   7. et al.

   Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: Results from the giant cohort. Ann Rheum Dis 2014;73:1186–9.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Braun J,
    2. Baraliakos X,
    3. Listing J,
    4. Davis J,
    5. van der Heijde D,
    6. Haibel H,
    7. et al.

    Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007;57:639–47.

    OpenUrlCrossRefPubMed